drugset / Trial / NCT04659304
Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
RandomizedSequentialOpen-labelTreatment
Summary
Phase 1b, multi-center, open label, sequential dose escalation trial assessing 3 dose cohorts using a 3+3 design to evaluate safety and tolerability of Allocetra-OTS in adult patients with moderate COVID-19. The sample size for this trial is anticipated to range from 9 to 18 patients.
Timeline
- Start
- 2021-12
- Primary completion
- 2022-09
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allocetra-OTS | Cell therapy | 5e+09 cells | Intravenous |
| Comparator | Allocetra-OTS | Cell therapy | 1e+10 cells | Intravenous |